Project leads
Collaborators

A Randomized Trial of Tac/MTX/bortezomib vs Tac/MTXplacebo in Allogeneic HSCT

Joseph H Antin

0 Collaborator(s)

Funding source

National Institutes of Health (NIH)

Follow

Joseph H Antin

Dana-Farber Cancer Institute

Boston, United States

Related projects

John D Schuetz

Metabolic pathways in leukemia

Effie W Petersdorf

Clinical Significance of MHC Haplotypes in HCT

Mark Y Chiang

Direct coregulation of Notch1 by Zmiz1 in T-cell leukemia

Hematology and hematologic malignancies

Gang Huang

Role of the Hypoxia-Inducible Factor-1alpha in Myelodysplastic Syndromes

Benjamin Levine Ebert

Development of Novel Therapeutic Strategies in Human Leukemias

Hesham M Amin

Role of IGF-IR tyrosine kinase in NPM-ALK-expressing T-cell lymphoma

Hodgkin lymphoma Non-Hodgkin lymphoma

Alan Rein

Retrovirus Assembly And Maturation

Pathology Hematology and hematologic malignancies

Christopher J Ott

Chemical Modulation of Chromatin Signaling in Lymphoid Malignancies

Hodgkin lymphoma Non-Hodgkin lymphoma Leukaemia

Oliver W Press

Pretargeted Radioimmunotherapy of CD20+ Lymphomas

Non-Hodgkin lymphoma

Hematology and hematologic malignancies Radiation Oncology Pathology